Amneal Pharmaceuticals, Inc.

NYSE:AMRX Stock Report

Mkt Cap: US$718.0m

Amneal Pharmaceuticals Financial Health

How is Amneal Pharmaceuticals's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AMRX's short term assets ($1.4B) exceed its short term liabilities ($818.0M).

Long Term Liabilities: AMRX's short term assets ($1.4B) do not cover its long term liabilities ($2.8B).


Debt to Equity History and Analysis

Debt Level: AMRX's net debt to equity ratio (1221.7%) is considered high.

Reducing Debt: AMRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable AMRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: AMRX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 23% per year.


Discover healthy companies